Phaseline

Targets › HDAC

HDAC: drug programs, companies and trials

14 programs from 13 companies in 29 trials: 22 Phase 2, 4 Phase 1, 3 Phase 3; Oncology, Other, Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: the race on HDAC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
HUYABIO InternationalHBI-8000
Histone deacetylase inhibitor
HDACPhase 3Unresectable or Metastatic MelanomaDec 2026
Chinese PLA General HospitalChidamide
PD-1 checkpoint inhibitor
HDAC, PDCD1Phase 3Newly Diagnosed Acute Myeloid Leukemia (AML); Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma; Acute Monocytic Leukemia; Relapsed/Refractory Acute Myeloid Leukemia …Jun 2027
BeBetter MedIfupinostat Hydrochloride for Injection (BEBT-908)
Histone deacetylase (HDAC) inhibitor
HDACPhase 3Relapsed/Refractory Diffuse Large B-Cell LymphomaDec 2028
The First Affiliated Hospital of Soochow UniversityChidamide
Histone deacetylase inhibitor
HDACPhase 2Acute Monocytic Leukemia; Acute Myeloid Leukemia; Acute Myeloid Leukemia, Adult; Adult T-cell Leukemia/Lymphoma …Dec 2026
Tianjin Medical University Cancer Institute and HospitalChidamide
Histone deacetylase (HDAC) inhibitor
HDAC, HDAC (class I/II)Phase 2Diffuse Large B-Cell Lymphoma-Recurrent; Metastatic Pancreatic Cancer; Diffuse Large B-Cell Lymphoma (DLBCL); Neuroblastoma (NB)Dec 2026
The First Hospital of Jilin UniversityChidamide
Histone deacetylase inhibitor
HDACPhase 2Metastatic Colorectal Cancer; Peripheral T Cell LymphomaJan 2027
Liu XiufengChidamide
Histone deacetylase (HDAC) inhibitor
HDACPhase 2Pancreatic Cancer, AdultMay 2027
The First Affiliated Hospital of Xiamen Universitychidaniline
Histone deacetylase inhibitor
HDACPhase 2Acute Myeloid LeukemiaJun 2027
China Medical University, ChinaChidamide
Histone deacetylase (HDAC) inhibitor
HDACPhase 2Small Cell Lung CancerOct 2027
Nanfang Hospital, Southern Medical UniversityChidamide
Histone deacetylase inhibitor
HDACPhase 2Acute Lymphoblastic LeukemiaJan 2028
University of California, Los AngelesFimepinostat
HDAC and PI3K inhibitor
HDAC, PIK3CAPhase 2Cushing DiseaseJan 2029
Massachusetts General HospitalCitarinostat
Histone deacetylase (HDAC) inhibitor
HDACPhase 1Smoldering Multiple MyelomaFeb 2027
The First Affiliated Hospital of Soochow UniversityIfupinostat Hydrochloride (BEBT-908)
HDAC inhibitor
HDACPhase 1B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Aug 2028
CG PharmaceuticalsIvaltinostat
Histone deacetylase (HDAC) inhibitor
HDACPhase 1Metastatic Pancreatic Adenocarcinoma–

Conditions

Acute Myeloid Leukemia (3) Acute Monocytic Leukemia (2) Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma (2) Small Cell Lung Cancer (2) Acute Myeloid Leukemia, Adult (1) Adult T-cell Leukemia/Lymphoma (1) Multiple Myeloma (1) Pancreatic Cancer, Adult (1) Metastatic Pancreatic Adenocarcinoma (1) B-cell Precursor Acute Lymphoblastic Leukemia (ALL) (1) Metastatic Colorectal Cancer (1) Peripheral T Cell Lymphoma (1)

Modalities

small molecule (7), antibody (5), mixed (2)

Companies

The First Affiliated Hospital of Soochow University (2) Liu Xiufeng (1) CG Pharmaceuticals (1) The First Hospital of Jilin University (1) Chinese PLA General Hospital (1) BeBetter Med (1) Tianjin Medical University Cancer Institute and Hospital (1) China Medical University, China (1) The First Affiliated Hospital of Xiamen University (1) HUYABIO International (1) University of California, Los Angeles (1) Nanfang Hospital, Southern Medical University (1) Massachusetts General Hospital (1)

Related targets

PDCD1 (1) HDAC (class I/II) (1) PIK3CA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.